Alzheimer's disease (AD), a progressive neurodegenerative disorder, is one of the leading causes of dementia worldwide, and currently has no definitive cure. Although antibody-based therapies that target amyloid β (Aβ) have recently been developed, their clinical effectiveness remains limited. These treatments can be costly and cause immune-related side effects, highlighting the need for safer, affordable, and widely accessible approaches that can slow the progression of AD.
from Medical Xpress - latest medical and health news stories https://ift.tt/4vctpHk
